Portal de investigación
Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Rodilla E
- Saura A
- Jiménez I
- Mendizábal A
- Pineda-Cantero A
- Lorenzo-Hernández E
- Fidalgo-Montero MDP
- López-Cuervo JF
- Rabadán-Pejenaute E
- Abella-Vázquez L
- Giner-Galvañ V
- Solís-Marquínez MN
- Boixeda R
- Peña-Fernández A
- Carrasco-Sánchez FJ
- González-Moraleja J
- Torres-Peña JD
- Guisado-Espartero ME
- Escobar-Sevilla J
- Guzmán-García M
- Martín-Escalante MD
- Martínez-González ÁL
- Casas-Rojo JM
- Gómez-Huelgas R
Grupos
Abstract
It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 ± 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.
Datos de la publicación
- ISSN/ISSNe:
- 2077-0383, 2077-0383
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.3390/jcm9103136
- PubMed:
- 32998337
Journal of Clinical Medicine MDPI
Citas Recibidas en Web of Science: 66
Documentos
- No hay documentos
Filiaciones
Keywords
- COVID-19, all-cause mortality, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), hypertension
Campos de Estudio
Cita
Rodilla E,Saura A,Jiménez I,Mendizábal A,Pineda A,Lorenzo E,Fidalgo MDP,López JF,GIL R,Rabadán E,Abella L,Giner V,Solís MN,Boixeda R,Peña A,Carrasco FJ,González J,Torres JD,Guisado ME,Escobar J,Guzmán M,Martín MD,Martínez ÁL,Casas JM,Gómez R. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. J. Clin. Med. 2020. 9. (10):3136. IF:4,242. (1).